SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Casasola V.)
 

Search: WFRF:(Casasola V.) > Management of Perip...

  • Leung, Ying-YingSingapore Gen Hosp, Dept Rheumatol & Immunol, Level 4, 20 Coll Rd, Singapore 169856, Singapore. (author)

Management of Peripheral Arthritis in Patients With Psoriatic Arthritis : An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • 2022-10-15
  • The Journal of Rheumatology,2023
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-499022
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-499022URI
  • https://doi.org/10.3899/jrheum.220315DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:for swepub-publicationtype

Notes

  • Objective We aimed to compile evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of psoriatic arthritis (PsA) for the revised 2021 Group in Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations.Methods A working group consisting of clinicians and patient research partners was convened. We reviewed the evidence from new randomized controlled trials (RCTs) for PsA treatment from February 19, 2013, to August 28, 2020. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-informed approach to derive evidence for the classes of therapeutic options for 3 patient groups: (1) naïve to treatment, (2) inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and (3) inadequate response to biologic DMARDs (bDMARDs). Recommendations were derived through consensus meetings.Results The evidence review included 69 RCTs. We derived GRADE evidence for each class of therapeutic options and achieved consensus for the recommendations. For patients naïve to treatment, the working group strongly recommends csDMARDs (methotrexate, sulfasalazine, leflunomide) and phosphodiesterase 4 inhibitors, and emphasizes regular assessment and early escalation to achieve treatment target. bDMARDs (tumor necrosis factor inhibitors [TNFi], interleukin 17 inhibitors [IL-17i], IL-12/23i, IL-23i) and Janus kinase inhibitors (JAKi) are also strongly recommended. For patients with inadequate response to csDMARDs, we strongly recommend TNFi, IL-17i, IL-12/23i, IL-23i, and JAKi. For those who had prior experience with bDMARDs, we strongly recommend a second TNFi, IL-17i, IL-23i, and JAKi. The evidence supporting nonpharmacological interventions was very low. An expert panel conditionally recommends adequate physical activity, smoking cessation, and diet to control weight gain.Conclusion Evidence supporting optimal therapy for the peripheral arthritis domain of PsA was compiled for the revised 2021 GRAPPA treatment recommendations.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • V. Korotaeva, TatianaSingapore Gen Hosp, Duke NUS Med Sch, Dept Rheumatol & Immunol, Singapore, Singapore.;VA Nasonova Res Inst Rheumatol, Moscow, Russia. (author)
  • Candia, LilianaUniv Juarez Estado Durango, Durango, Mexico. (author)
  • Pedersen, Susanne JuhlRigshosp, Ctr Rheumatol & Spine Dis, Copenhagen, Denmark. (author)
  • Molano, Wilson BautistaUniv Bosque, Univ Hosp Fdn Santa Fe Bogota, Bogota, Colombia. (author)
  • Ruderman, Eric M.Northwestern Univ, Feinberg Sch Med, Chicago, IL USA. (author)
  • Bisoendial, RadjeshMaasstad Hosp, Rotterdam, Netherlands. (author)
  • Perez-Alamino, RodolfoHosp Avellaneda, Rheumatol Sect, San Miguel De Tucuman, Argentina. (author)
  • Olsder, WendyEindhoven Univ Technol, Sch Ind Engn, Eindhoven, Netherlands. (author)
  • Moeller, BurkhardUniv Hosp Bern, Dept Rheumatol & Immunol, Inselspital, Bern, Switzerland. (author)
  • Grazio, Simeon (author)
  • Gudu, TaniaCambridge Univ Hosp NHS FT, Rheumatol Dept, Cambridge, Cambs, England. (author)
  • Mody, Girish M.Univ KwaZulu Natal, Dept Rheumatol, Durban, South Africa. (author)
  • Pineda, CarlosInst Nacl Rehabil Luis Guillermo Ibarra Ibarra, Mexico City, Mexico. (author)
  • Raffayova, HelenaNatl Inst Rheumat Dis, Piestany, Slovakia. (author)
  • Rohekar, SherryWestern Univ, London, ON, Canada. (author)
  • Goldenstein-Schainberg, ClaudiaUniv Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, Brazil. (author)
  • Urena, Sergio R. GutierrezUniv Guadalajara, Hosp Civil Guadalajara FAA, Guadalajara, Mexico. (author)
  • Vargas, Julio Cesar CasasolaUniv Nacl Autonoma Mexico, Hosp Gen Mexico, Mexico City, Mexico. (author)
  • Meghnathi, BhowmikCIMS Hosp, Dept Rheumatol & Clin Immunol, Ahmadabad, India. (author)
  • Prasad, RoopaUniv Hosp Wales, Cardiff, Wales. (author)
  • Richette, PascalUniv Paris, Hop Lariboisiere, Rheumatol Dept, INSERM U1132, Paris, France. (author)
  • Miranda, Jose Roberto S. (author)
  • Malliotis, NikolasUppsala Univ Hosp, Dept Rheumatol, Uppsala, Sweden (author)
  • Lindqvist, Ulla,1948-Uppsala universitet,Reumatologi(Swepub:uu)ullalq (author)
  • Simon, DavidFriedrich Alexander Univ Erlangen Nurnberg & Unive, Dept Internal Med 3, Rheumatol & Immunol, Erlangen, Germany.;Univ Klinikum Erlangen, Erlangen, Germany. (author)
  • Ezeonyeli, AmaraSt Georges Univ Hosp NHS Fdn Trust, London, England. (author)
  • Soriano, Enrique R.Hosp Italiano Buenos Aires, Rheumatol Unit, Buenos Aires, Argentina.;Hosp Italiano Buenos Aires, Univ Inst, Buenos Aires, Argentina. (author)
  • FitzGerald, OliverUniv Coll Dublin, Conway Inst Biomol Res, Dublin, Ireland. (author)
  • Singapore Gen Hosp, Dept Rheumatol & Immunol, Level 4, 20 Coll Rd, Singapore 169856, Singapore.Singapore Gen Hosp, Duke NUS Med Sch, Dept Rheumatol & Immunol, Singapore, Singapore.;VA Nasonova Res Inst Rheumatol, Moscow, Russia. (creator_code:org_t)

Related titles

  • In:Journal of Rheumatology: The Journal of Rheumatology50:1, s. 119-1300315-162X1499-2752

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view